Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV 89106, USA.
Biogen, Cambridge, MA 02142, USA.
Neurodegener Dis Manag. 2024;14(2):21-33. doi: 10.2217/nmt-2023-0047. Epub 2024 Apr 16.
To assess time to improvement in Quality of Life in Neurological Disorders (Neuro-QoL) domains for patients treated with natalizumab versus ocrelizumab. Patients enrolled in the MS PATHS network who initiated treatment with either natalizumab or ocrelizumab rated the Neuro-QoL domains of physical function, symptoms, emotional health, cognitive function and social ability. Time to clinically meaningful improvement was significantly shorter with natalizumab versus ocrelizumab for cognitive function (event time ratio [95% CI]: 0.37 [0.24-0.57]; p < 0.001), sleep disturbance (0.45 [0.28-0.72]; p = 0.001), social role participation (0.37 [0.21-0.66]; p = 0.001) and social role satisfaction (0.5 [0.31-0.8]; p = 0.004). Natalizumab had shorter time to clinically meaningful improvement in cognitive, sleep, and social role Neuro-QoL domains versus ocrelizumab.
评估接受那他珠单抗和奥瑞珠单抗治疗的患者在神经疾病生活质量（Neuro-QoL）领域的改善时间。 加入 MS PATHS 网络的患者开始接受那他珠单抗或奥瑞珠单抗治疗，对神经疾病生活质量的身体功能、症状、情绪健康、认知功能和社会能力领域进行评分。 与奥瑞珠单抗相比，那他珠单抗在认知功能（事件时间比[95%CI]：0.37[0.24-0.57]；p<0.001）、睡眠障碍（0.45[0.28-0.72]；p=0.001）、社会角色参与（0.37[0.21-0.66]；p=0.001）和社会角色满意度（0.5[0.31-0.8]；p=0.004）方面的临床意义上的改善时间更短。 与奥瑞珠单抗相比，那他珠单抗在认知、睡眠和社会角色神经疾病生活质量领域的临床意义改善时间更短。
